Mycophenolate mofetil monotherapy in liver transplant recipients

Clinical Transplantation

Volumn 25, Issue 6, 2011, Pages

  Kriss, Michael ^a   Sotil, Eva U ^b   Abecassis, Michael ^c   Welti, Mary ^c   Levitsky, Josh ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Calcineurin inhibitors; Conversion; Nephropathy; Nephrotoxicity; Rejection

Indexed keywords

ACICLOVIR; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; ERYTHROPOIETIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC PATIENT; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; GRAFT REJECTION; HERPES ZOSTER; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MALE; MONOTHERAPY; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; STROKE; TREATMENT OUTCOME;

ADULT; AGED; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 83555173523     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2011.01512.x     Document Type: Article

References (39)

1. Calne RY, Rolles K, White DJ et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979: 2: 1033.
2. Gordon RD, Shaw BW Jr, Iwatsuki S, Esquivel CO, Starzl TE. Indications for liver transplantation in the cyclosporine era. Surg Clin North Am 1986: 66: 541.
3. Wijdicks EF, Wiesner RH, Krom RA. Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression. Neurology 1995: 45: 1962.
4. Fernandez LA, Lehmann R, Luzi L et al. The effects of maintenance doses of FK506 versus cyclosporin A on glucose and lipid metabolism after orthotopic liver transplantation. Transplantation 1999: 68: 1532.
5. Mueller AR, Platz KP, Bechstein WO et al. Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994: 58: 155.
6. Mueller AR, Platz KP, Christe W, Bechstein WO, Blumhardt G, Neuhaus P. Severe neurotoxicity after liver transplantation: association between FK 506 therapy and hepatitis C virus disease. Transplant Proc 1994: 26: 3131.
7. Platz KP, Mueller AR, Blumhardt G et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994: 58: 170.
8. Canzanello VJ, Textor SC, Taler SJ et al. Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506). Liver Transpl Surg 1998: 4: 328.
9. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984: 311: 699.
10. Wilkinson A, Pham PT. Kidney dysfunction in the recipients of liver transplants. Liver Transpl 2005: 11(Suppl 2): S47.
11. Moreno JM, Cuervas-Mons V, Rubio E et al. Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality. Transplant Proc 2003: 35: 1907.
12. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003: 349: 931.
13. Schlitt HJ, Barkmann A, Boker KH et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001: 357: 587.
14. Farkas SA, Schnitzbauer AA, Kirchner G, Obed A, Banas B, Schlitt HJ. Calcineurin inhibitor minimization protocols in liver transplantation. Transpl Int 2009: 22: 49.
15. Beckebaum S, Klein C, Varghese J et al. Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients. Aliment Pharmacol Ther 2009: 30: 834.
16. Sievers TM, Rossi SJ, Ghobrial RM et al. Mycophenolate mofetil. Pharmacotherapy 1997: 17: 1178.
17. Bilbao I, Castells L, Rojas L et al. Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients. Int Immunopharmacol 2006: 6: 1977.
18. Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001: 357: 609.
19. Moreno Planas JM, Cuervas-Mons Martinez V, Rubio Gonzalez E et al. Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant 2004: 4: 1650.
20. Fairbanks KD, Thuluvath PJ. Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience. Liver Transpl 2004: 10: 1189.
21. Barrera Pulido L, Alamo Martinez JM, Pareja Ciuro F et al. Efficacy and safety of mycophenolate mofetil monotherapy in liver transplant patients with renal failure induced by calcineurin inhibitors. Transplant Proc 2008: 40: 2985.
22. Detry O, De Roover A, Honore P, Delwaide J, Jacquet N, Meurisse M. Mycophenolate mofetil monotherapy in stable liver transplant recipients with progressive renal failure. Transplant Proc 2002: 34: 782.
23. Jimenez-Perez M, Lozano Rey JM, Marin Garcia D, Olmedo Martin R, De La Cruz Lombardo J, Rodrigo Lopez JM. Efficacy and safety of monotherapy with mycophenolate mofetil in liver transplantation. Transplant Proc 2006: 38: 2480.
24. Moreno JM, Rubio E, Gomez A et al. Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation. Transplant Proc 2003: 35: 1874.
25. Pierini A, Mirabella S, Brunati A, Ricchiuti A, Franchello A, Salizzoni M. Mycophenolate mofetil monotherapy in liver transplantation. Transplant Proc 2005: 37: 2614.
26. Raimondo ML, Dagher L, Papatheodoridis GV et al. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation 2003: 75: 186.
27. Papatheodoridis GV, O'Beirne J, Mistry P, Davidson B, Rolles K, Burroughs AK. Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: a preliminary report. Transplantation 1999: 68: 155.
28. Orlando G, Baiocchi L, Cardillo A et al. Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension. Liver Transpl 2007: 13: 46.
29. Dharancy S, Iannelli A, Hulin A et al. Mycophenolate mofetil monotherapy for severe side effects of calcineurin inhibitors following liver transplantation. Am J Transplant 2009: 9: 610.
30. Manrique A, Jimenez C, Ortega P et al. Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis. Transplant Proc 2008: 40: 2962.
31. Herrero JI, Quiroga J, Sangro B et al. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transpl Surg 1999: 5: 414.
32. Ko HH, Greanya E, Lee TK, Steinbrecher UP, Erb SR, Yoshida EM. Mycophenolate mofetil in liver transplant patients with calcineurin-inhibitor-induced renal impairment. Ann Hepatol 2008: 7: 376.
33. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999: 130: 461.
34. Hong F, Lee J, Song JW et al. Cyclosporin A blocks muscle differentiation by inducing oxidative stress and inhibiting the peptidyl-prolyl-cis-trans isomerase activity of cyclophilin A: cyclophilin A protects myoblasts from cyclosporin A-induced cytotoxicity. FASEB J 2002: 16: 1633.
35. Cartier R, Dagenais F, Hollmann C, Cambron H, Buluran J. Chronic exposure to cyclosporine affects endothelial and smooth muscle reactivity in the rat aorta. Ann Thorac Surg 1994: 58: 789.
36. Hong F, Lee J, Piao YJ et al. Transgenic mice overexpressing cyclophilin A are resistant to cyclosporin A-induced nephrotoxicity via peptidyl-prolyl cis-trans isomerase activity. Biochem Biophys Res Commun 2004: 316: 1073.
37. Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998: 66: 59.
38. Sheiner PA, Magliocca JF, Bodian CA et al. Long-term medical complications in patients surviving > or = 5years after liver transplant. Transplantation 2000: 69: 781.
39. Hwang S, Lee SG, Ahn CS et al. A clinical assessment of mycophenolate drug monitoring after liver transplantation. Clin Transplant 2010: 24: E35.